Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCSL Behring
About this trial
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Eligibility criteria
Qualifiers
Adult patient (aged ≥18 years)
Patients suffering from CIDP according to EAN/PNS 2021 criteria
Planned switch from IVIg to Hizentra®
Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
Disqualifiers
Concomitant participation in an interventional clinical study
Trial design
Treatments tested in this trial
- Hizentra
Treatment groups
No treatment groups listed
Locations
27CHU Amiens Picardie 180054, Amiens France
CHU Angers Angers France
Hôpital privé de La Casamance Aubagne France
CH Bayonne Bayonne France
Sponsors and collaborators
CSL Behring
Lead sponsor
Source ClinicalTrials.gov